Ultra High-Risk Myeloma
|
|
- Dinah Lyons
- 5 years ago
- Views:
Transcription
1 UNDERSTANDING AND MANAGING ULTRA HIGH-RISK HEMATOLOGIC MALIGNANCIES Ultra High-Risk Myeloma Hervé Avet-Loiseau 1 1 Laboratoire d Hématologie, Institut de Biologie, Nantes, France Ultra high-risk myeloma can be defined as myeloma leading to death within 24 months. Despite tremendous improvements in the past decade (especially because of the availability of novel drugs such as thalidomide, bortezomib, and lenalidomide), these patients still represent 15% to 20% of the patients. Many prognostic factors can help to define these patients, including age, renal insufficiency, poor performance status, comorbities, International Staging System (ISS) stage 3, high proliferation, leukemic presentation, and acquired genetic changes, as defined by interphase fluorescence in situ hybridization or genomics. Several combinations of these prognostic parameters can define ultra high-risk patients, making a universal therapeutic proposal almost impossible. However, focusing on fit patients with ISS 3, high proliferation, and poor-risk genetic changes, these patients should probably benefit from dose-dense and prolonged therapeutic schemas, ideally within prospective trials. For a long time, the prognosis of multiple myeloma (MM) has been poor with limited treatment options. Many studies reported a median overall survival of less than 3 years. The first glimpse of improved outcomes was reports in the 1990s of the use of high-dose melphalan with stem cell support. 1 3 Using a polychemotherapy-based induction, followed by one or two courses of high-dose melphalan, the median overall survival improved to 5 years. However, more than one-half of the patients are not eligible for these intensive approaches. In the past decade, tremendous progresses have been observed, with the availability of three major new drugs: (1) thalidomide, (2) bortezomib, and (3) lenalidomide. With the use of these drugs, most commonly in combination with high-dose melphalan, patients now display a much better outcome The latest estimates of median overall survival are probably around 10 years for patients under age 65 and around 5 to 6 years for older patients (Intergroupe Francophone du Myélome [IFM], personal communication, 2010). However, despite this remarkable progress, we have recognized that not all patients enjoy such a long survival. Some patients present with highly refractory MM or exhibit early relapses after an initial response. The three objectives of this paper are to (1) try and define who these patients are, (2) recognize these patients at the time of diagnosis, and (3) propose specific therapeutic approaches to improve their outcome. Prognostic Parameters The definition of these ultra high-risk patients is by definition arbitrary. This review focuses on patients with a median overall survival of less than 2 years. Many papers have described a huge number of prognostic factors in MM. Among this list, we can focus on those who have been confirmed by several studies. A nonexhaustive list comprises a high serum 2 -microglobulin; a high C-reactive protein level; a low albumin level; a high creatinine level; a high lactate dehydrogenase level; a low hemoglobin level; a low platelet count; a high labeling index; leukemic presentation; poor cytogenetic parameters (eg, t(4;14), del(17p), or t(14;16)); and, as usual in oncology, older age. In this list, the most important parameters are probably 2 -microglobulin, proliferation, and genetic abnormalities (Table 1) In a large cohort of more than 12,000 patients, the International Myeloma Working Group described an International Staging System (ISS) based on 2 -microglobulin and albumin levels. 13 This prognostic model classifies the patients into three groups, with different overall survival (62 months, 44 months, and 29 months for stages 1, 2, and 3, respectively). This system allows great progress in prognostication at the population level, but is more limited at the individual level. The weakness of this model is that it does not take into account intrinsic prognostic parameters, such as proliferation or genetic abnormalities. An ideal prognostic model would probably combine 2 -microglobulin level (or ISS) that reflects tumor mass, renal insufficiency, and general patient condition, a marker of plasma cell proliferation (measured by labeling index or conventional cytogenetics) and genetic changes. The best way to identify these genetic changes is so far not defined. Many techniques can be used, including interphase fluorescence in situ hybridization (ifish), gene expression profiling (GEP), or DNA copy number changes (analyzed by comparative genome hybridization [CGH] array or single nucleotide polymorphism [SNP] array). 25,26 Most large series have used ifish. The weakness of this technique in MM is that it requires plasma cell identification and that it allows the analysis of only a small number of chromosomal abnormalities. Despite these limitations, it has been shown that t(4;14) and del(17p) are major prognostic factors, at least in patients treated before the novel drug era An updated ISS effort did show that karyotype abnormalities (reflecting high proliferation) and genetic changes (as identified by ifish) significantly improved the ISS model (Enhancement of ISS Staging System incorporating genetic changes: an International Myeloma Working Group (IMWG) collaborative project, unpublished data). High-throughput molecular technologies (GEP and CGH array/snp array) are probably more powerful, because they analyze all the abnormalities observed throughout the whole genome. However, these technologies require plasma cell purification and highly specifically dedicated platforms (including bioinformatics), and are not widely available to most physicians. The next question is the stability of these prognostic factors in the novel drug era. Most (if not all) of them have been defined in retrospective cohorts of patients treated before the wide use of thalidomide, bortezomib, and lenalidomide. The current question is whether these prognostic parameters are still valid with novel treatment modalities? Hematology
2 Table 1. Summary of the most prognostic parameters defining ultra high-risk patients Parameters Poor-prognosis values International Staging System (ISS) Stage 3 β2-microglobulin Plasma cell leukemia 17p deletion Gene expression profiling > 5.5 mg/l Present UAMS 70-gene model or IFM 15-gene model Definition of Ultra High-Risk Patients The ISS is probably still prognostic with novel combinations. Even though few studies specifically addressed this issue, most of the recently published trials showed that patients with ISS stage 3 displayed a shorter survival. 7,10,27 This statement is probably also true for highly proliferative disease. Here, again, few studies did analyze this question. In patients treated at the University of Arkansas Total Therapy 3 program (polychemotherapy induction, double intensive melphalan, consolidation, and long-term maintenance with bortezomib-lenalidomide-dexamethasone cycles), an abnormal karyotype (indirectly reflecting plasma cell proliferation) is a powerful prognostic parameter. 27 Similarly, a small study from the Mayo Clinic suggested that a high labeling index was still prognostic in patients treated with lenalidomide-dexamethasone. 16 The same question addressed to genetic changes is still evolving. Some preliminary reports suggested that bortezomib was able to overcome the prognostic value of t(4;14). This has been first suggested in the VISTA (Velcade as Initial Standard Therapy in Multiple Myeloma) trial (comparing melphalan-prednisone vs bortezomib-melphalan-prednisone). 28 In a very small number of patients (26 patients) presenting either t(4;14), del(17p), or t(14;16), time to progression and overall survival were similar in the bortezomib arm to that of patients lacking these chromosomal abnormalities (limiting the stability of the conclusions given limited power). The second report came from the Arkansas Total Therapy 3 program that showed that t(4;14), but also del(17p), were not anymore prognostic factors with this very peculiar therapy program. 27,29 More recently, the IFM did show that a short-term bortezomib-dexamethasone (BD) induction significantly improved the outcome (both for event-free survival and overall survival) of patients with t(4;14), but not that of patients with del(17p). 30 Nevertheless, even among bortezomib-treated patients, the t(4; 14)(p16;q32) remains a significant prognostic factor Thus, based on ifish and GEP analyses, t(4;14) is probably no longer a (strong) prognostic factor in patients treated with bortezomib. Because the VISTA trial and the Arkansas results showed a complete overcoming of the prognostic value of t(4;14), in contrast to the IFM data that showed only a partial improvement, it can be suggested that long-term treatment with bortezomib is recommended for these patients. Further validation, however, is needed. The case of patients with del(17p) is less clear. All of the recently published reports showed that del(17p) remains a strong prognostic factor. 16,31 The only study suggesting that del(17p) was no longer prognostic came from the Arkansas group. 29 Based on GEP analysis, using a surrogate proposal to detect -17p13, they showed that patients with a low TP53 expression encountered a similar outcome than patients with normal TP53 expression in the Total Therapy 3 program. Some authors (especially those from Arkansas University) claim that all the patients should be analyzed by GEP to define a really strong prediction for survival. The first question is the feasibility of GEP in the routine practice. In a multicenter setting, only about half of the patients are analyzable with this technique (Avet-Loiseau H, Institut de Biologie, oral communication, September 17, 2010), because of the quality of the bone marrow samples sent to the laboratory. The second question is the definition of ultra high-risk patients using these technologies. Two reports on large cohorts of patients analyzed with GEP have been published so far (Figure 1). 22,24 These two studies defined two different sets of genes identifying high-risk patients. Whether these models are identifying the same group of high-risk patients is an unresolved question. First, the two models were built on different platforms. Moreover, these models have been built on patients treated very differently. The Arkansas model was based on patients treated in the Total Therapy 2 program (polychemotherapy induction, double intensive melphalan, consolidation, long-term thalidomide maintenance), whereas the IFM model was built on patients treated with a vincristineadriamycin-dexamethasone (VAD) induction, followed by double Figure 1. Genomic data showing the predictability of ultra high-risk myeloma patients using genomics. (A) Arkansas model using gene expression profiling. (B) IFM model using the SNP array. 490 American Society of Hematology
3 Table 2. Suggestions for treatment of ultra high-risk patients Patients with t(4;14) Bortezomib-based chemotherapy Patients with renal insufficiency Patients with del(17p), or poor-risk GEP Bortezomib-based chemotherapy Dose-dense chemotherapy (prospective trials) Plasma cell leukemia Role of consolidation and/or maintenance? high-dose melphalan. A temptative cross-validation has been performed and showed a weak confirmation. This can be due to the different platforms, but also to the different therapeutic strategies. Despite these technical limitations, it seems that GEP is promising to define high-risk patients. Another study from the IFM using SNP array did show that some genomic changes (eg, 1q gains, trisomy 5, or 12p deletions) allowed identification of patients with very different outcomes. 26 But, again, this technology requires plasma cell purification and is probably not usable for all the patients in a multicenter setting. Ultra high-risk patients could be defined by ISS stage 3, a high plasma cell proliferation, and the presence of specific genetic changes, including del(17p) and probably other genomic abnormalities that need further work for a widely accepted definition. A specific statement is mandatory for the rare patients presenting with primary plasma cell leukemia. Even though no large study specifically dedicated for this patient population exists in the literature, most authors agree to consider these patients as high-risk (and probably ultra high-risk) Actually, these patients often combine a high 2 -microglobulin level (or ISS stage 3), a high proliferative index reflected by the frequent abnormal karyotype and poor risk genetic abnormalities. Management of Ultra High-Risk Patients Even though the definition of ultra high-risk MMs varies from institution to institution, their management is very disappointing. For instance, in the Arkansas definition based on GEP, these patients represent 13% of all MMs. Even using extremely intensive and prolonged therapy, these patients display a very poor outcome. 22 Using more classical therapies based on bortezomibdexamethasone induction, followed by one or two courses of high-dose melphalan for younger patients, patients with del(17p) present a short, event-free survival and overall survival. Thus, how can this poor outcome be improved? Several strategies have been tested. If considering the youngest patients (younger than age 65 or 70), several induction combinations (before high-dose therapy) have addressed this issue. These combinations included VAD, TD (thalidomide-dexamethasone), BD, or more complex strategies such as VTD-PACE (bortezomibthalidomide-dexamethasone-cisplatinum-adriamycin-cyclophosphamide-etoposide). Despite some improvements in the complete response rates, a similar number of patients still died rapidly in all combination schemes. Then, some investigators worked on the high-dose regimen. A double-intensive strategy does not seem to benefit these patients. 3 A combination of high-dose melphalan with bortezomib seemed to increase the response rate, but no data are available for overall survival. 35 Finally, different consolidation/ maintenance strategies have been tested. Thalidomide maintenance is definitely not the solution. 36,37 Long-term maintenance with lenalidomide seems to improve the progression-free survival, but no data are available for overall survival (that could be shortened by the appearance of specific or overall resistances at relapse) or for high-risk patients (Attal M, personal communication, August 2010). Iterative long-term reinductions with bortezomib-lenalidomidedexamethasone combinations appear promising for patients with t(4;14) or del(17p), but a population (representing about 13% of the patients) still escapes to this strategy and presents early death (Table 2). 38 If a solution does exist, it will definitely be found through specific therapeutic trials. For instance, a trial testing dose-dense chemotherapy, prolonged over a long period of time, could be a solution to try to maintain a continuous therapeutic pressure on the clone. Another possibility could be to propose a frontline myeloablative stem cell transplant for such patients younger than age 50. These phase 2 trials should typically be multicentric, possibly international, to test different approaches over a short period of time. An important limit of this trial approach is that many of these poor-risk patients are not eligible for trial enrollment because of poor performance status, renal insufficiency, or comorbidities. Some investigators propose to test new drugs in these ultra high-risk patients. This proposal is highly debatable. The risk is to kill promising drugs tested on highly resistant patients. A strategy is recommended in which modern prognostic parameters (including genomics) would be analyzed in phase 2 and phase 3 trials testing novel drugs eg, carfilzomib (second-generation proteasome inhibitor), pomalidomide (novel IMID [imidazoline]), heat shock protein, or histone deacetylase inhibitors to specifically analyze their efficacy on high-risk patients. Disclosures Conflict-of-interest disclosure: The author is on the Board of Directors and Advisory Committees for Janssen-Cilag and Celgene. Off-label drug use: None disclosed. Correspondence Hervé Avet-Loiseau MD, PhD, Professor, Laboratoire d Hématologie, Institut de Biologie, 9 Quai Moncousu, Nantes Cedex 09, France; Phone: ; Fax: ; herve.avetloiseau@chu-nantes.fr References 1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996;335: Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348: Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349: Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with Hematology
4 multiple myeloma: randomised controlled trial. Lancet. 2006; 367: Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99 06): a randomised trial. Lancet. 2007;370: Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352: Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM Phase III Trial. J Clin Oncol Sep 7. [Epub ahead of print]. 8. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357: Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357: Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus lowdose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11: Bataille R, Durie BG, Grenier J. Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol. 1983;55: Durie BG, Stock-Novack D, Salmon SE, et al. Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study. Blood. 1990;75: Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23: Greipp PR, Katzmann JA, O Fallon WM, Kyle RA. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood. 1988;72: Shaughnessy J, Jacobson J, Sawyer J, et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood. 2003;101: Kapoor P, Kumar S, Fonseca R, et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2009;114: Facon T, Avet-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2- microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood. 2001;97: Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101: Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood. 2005;106: Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101: Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood. 2007;10: Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109: Mulligan G, Mitsiades C, Bryant B, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007;109: Decaux O, Lodé L, Magrangeas F, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2008;26: Carrasco DR, Tonon G, Huang Y, et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell. 2006;9: Avet-Loiseau H, Li C, Magrangeas F, et al. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol. 2009;27: Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007;138: San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359: Shaughnessy JD, Zhou Y, Haessler J, et al. TP53 deletion is not an adverse feature in multiple myeloma treated with Total Therapy 3. Br J Haematol. 2009;147: Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol Aug 9. [Epub ahead of print]. 31. Reece D, Song KW, Fu T, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood. 2009;114: Avet-Loiseau H, Daviet A, Brigaudeau C, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique Hématologique Blood. 2001;97: Musto P, Rossini F, Gay F, et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer. 2007;109: Ramsingh G, Mehan P, Luo J, Vij R, Morgensztern D. Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and Cancer. 2009;115: Roussel M, Moreau P, Huynh A, et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood. 2010;115: Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108: American Society of Hematology
5 37. Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol. 2009;27: Nair B, van Rhee F, Shaughnessy JD Jr, et al. Superior results of Total Therapy 3 ( ) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial with bortezomib, lenalidomide and dexamethasone (VRD) maintenance. Blood Feb 2. [Epub ahead of print]. Hematology
Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma
930 Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma NIAN LIU, HEBING ZHOU, GUANGZHONG YANG, CHUANYING GENG, YUAN JIAN, HUAN GUO and WENMING CHEN Department
More informationVI. Autologous stem cell transplantation and maintenance therapy
Hematological Oncology Hematol Oncol 2013; 31 (Suppl. 1): 42 46 Published online in Wiley Online Library (wileyonlinelibrary.com).2066 Supplement Article VI. Autologous stem cell transplantation and maintenance
More informationTherapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients
EXPERIMENTAL AND THERAPEUTIC MEDICINE 6: 977-982, 2013 Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients CHENGCHENG FU, JUAN WANG, XUE XIN, HUI LIU,
More informationStrategies for Risk-Adapted Therapy in Myeloma. Mayo Clinic Arizona Cancer Center; Professor of Medicine; Scottsdale, AZ
Multiple Myeloma Session Chair: Paul Richardson, MD Speakers: Rafael Fonseca, MD; Michel Attal, MD; and Paul Richardson, MD Strategies for Risk-Adapted Therapy in Myeloma Rafael Fonseca Mayo Clinic Arizona
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationP53 Gene Deletion Detected By Fluorescence In Situ Hybridization is an Adverse
Blood First Edition Paper, prepublished online August 31, 2004; DOI 10.1182/blood-2004-04-1363 P53 Gene Deletion Detected By Fluorescence In Situ Hybridization is an Adverse Prognostic Factor for Patients
More informationChoosing upfront and salvage therapy for myeloma in the ASEAN context
Choosing upfront and salvage therapy for myeloma in the ASEAN context Daryl Tan Consultant Department of Haematology Singapore General Hospital Adjunct Assistant Professor Duke-NUS Graduate Medical School
More informationMultiple Myeloma in the Elderly: When to Treat, When to Go to Transplant
Multiple Myeloma in the Elderly: When to Treat, When to Go to Transplant Review Article [1] October 15, 2010 By Jean-luc Harousseau, MD [2] Until recently, standard treatment of multiple myeloma (MM) in
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationChromosomal Aberrations þ1q21 and del(17p13) Predict Survival in Patients With Recurrent Multiple Myeloma Treated With Lenalidomide and Dexamethasone
Chromosomal Aberrations þ1q21 and del(17p13) Predict Survival in Patients With Recurrent Multiple Myeloma Treated With Lenalidomide and Dexamethasone Ulrike Klein, MD 1 ; Anna Jauch, PhD 2 ; Thomas Hielscher
More informationMyeloma Support Group: Now and the Horizon. Brian McClune, DO
Myeloma Support Group: Now and the Horizon Brian McClune, DO Disclosures Consultant to Celgene Objectives Transplant for myeloma- is there any thing new? High risk disease University protocols New therapies?
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationJ Clin Oncol 29: by American Society of Clinical Oncology INTRODUCTION
VOLUME 29 NUMBER 14 MAY 1 211 JOURNAL OF CLINICAL ONCOLOGY R E V I E W A R T I C L E Molecular Heterogeneity of Multiple Myeloma: Pathogenesis, Prognosis, and Therapeutic Implications Hervé Avet-Loiseau,
More informationApproach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of
More informationManaging Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient. Case Study
Managing Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient Case Study 2 2011 Newly Diagnosed Patient The patient is a 61-year-old Caucasian female History of high blood pressure
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationASBMT. Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma
Biol Blood Marrow Transplant 19 (2013) 445e449 Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma Emilie Lemieux 1,y, Cyrille Hulin 2,y, Denis Caillot 3, Stéphanie Tardy
More informationModified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
ORIGINAL ARTICLE 218 Oct 26. [Epub ahead of print] https://doi.org/1.394/kjim.218.144 Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
More informationA.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified)
chapter 4 The significance of monoclonal plasma cells in the bone marrow biopsies of patients with multiple myeloma following allogeneic or autologous stem cell transplantation A.M.W. van Marion H.M. Lokhorst
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More information37 Novel Therapies for
37 Novel Therapies for Multiple Myeloma Abstract: Current standard of management for newly diagnosed multiple myeloma are continuously evolving due to the advent of a number of novel agents with different
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationModule 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning
Module 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning Challenge Question: Role of Autologous Stem Cell Transplant Which of the following is true about eligibility for high-dose
More informationRefractory M ultiple Multiple M yeloma Myeloma
Refractory Multiple Myeloma A Case Study Case: #1 48-Year-Old Male Presented to the ER with Fatigue and Acute Severe Lower Back Pain Patient assessment: X-ray of lumbar spine: L4 compression fracture,
More informationCOMy Congress A New Era of Advances in Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
A New Era of Advances in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 9: , 2015
EXPERIMENTAL AND THERAPEUTIC MEDICINE 9: 1895-1900, 2015 Clinical characteristics of a group of patients with multiple myeloma who had two different λ light chains by immunofixation electrophoresis: A
More informationMultiple myeloma, 25 (45) years of progress. The IFM experience in patients treated with frontline ASCT. Philippe Moreau, Nantes
Multiple myeloma, 25 (45) years of progress The IFM experience in patients treated with frontline ASCT Philippe Moreau, Nantes Shibata T. Prolonged survival in a case of multiple myeloma treated with high
More informationKEY WORDS: Multiple myeloma, Complete remission, Prognostic factor, Overall survival, Autologous stem cell transplantation
Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront Single Autologous Transplantation Jin Seok Kim,
More informationNew Questions About Transplantation in Multiple Myeloma
Review Article [1] September 01, 2006 By Parameswaran Hari, MD, MRCP [2], Marcelo C. Pasquini [3], and David H. Vesole, MD, PhD [4] Multiple myeloma is now the most common indication for autologous stem
More informationMYBORPRE. Protocol Code. Lymphoma, Leukemia/BMT. Tumour Group. Dr. Kevin Song. Contact Physician
BC Cancer Protocol Summary for the Treatment of Multiple Myeloma Using Bortezomib, Dexamethasone With or Without Cyclophosphamide as Induction Pre-Stem Cell Transplant Protocol Code Tumour Group Contact
More informationARTICLES. Introduction. Methods. Study design This study is a prospective, non-randomized clinical trial. The trial
Multiple Myeloma ARTICLES Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional
More informationAperTO - Archivio Istituzionale Open Access dell'università di Torino
AperTO - Archivio Istituzionale Open Access dell'università di Torino Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis
More informationSerum Free Light Chains should be the target of response evaluation in light chain myeloma rather than urines: results from the IFM 2009 trial
Serum Free Light Chains should be the target of response evaluation in light chain myeloma rather than urines: results from the IFM 2009 trial Jill Corre*, Thomas Dejoie, Helene Caillon, Michel Attal*,
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationMULTIPLE MYELOMA AFTER AGE OF 80 YEARS
MULTIPLE MYELOMA AFTER AGE OF 80 YEARS C. Hulin CHU Nancy, France Intergroupe Francophone du Myelome (IFM) Epidemiology SEER Program between 1990-2004: 17 330 MM cases, 51% 70 y and 20% 80 y. Brenner et
More informationManagement of Multiple Myeloma
Management of Multiple Myeloma Damian J. Green, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance New Treatment Options Have Improved OS in MM Kumar SK, et al. Blood. 2008;111:2516-2520.
More informationBortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
VOLUME 45 ㆍ NUMBER 3 ㆍ September 2010 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma Se
More informationKEY WORDS: Multiple myeloma, Autologous transplantation, Induction therapy
Short Course Bortezomib plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Nontransplant Candidates in Patients with Previously Untreated Multiple Myeloma Cristina
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationmsmart Mayo Stratification for Myeloma And Risk-adapted Therapy Newly Diagnosed Myeloma
msmart Mayo Stratification for Myeloma And Risk-adapted Therapy Newly Diagnosed Myeloma msmart Multiple myeloma is increasingly recognized as more than one disease, characterized by marked cytogenetic,
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationUpfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum
Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic
More informationStem Cell Transplantation in Multiple Myeloma
Stem Cell Transplantation in Multiple Myeloma Michel Attal, Philippe Moreau, Herve Avet-Loiseau, and Jean-Luc Harousseau Service d Hématologie, Hôpital Purpan, Toulouse, France Multiple myeloma (MM) is
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationD.J. White MD MSc,* N. Paul PhD, D.A. Macdonald MD,* R.M. Meyer MD, and L.E. Shepherd MD ORIGINAL ARTICLE ABSTRACT KEY WORDS 1.
ORIGINAL ARTICLE Addition of lenalidomide to melphalan in the treatment of newly diagnosed multiple myeloma: the National Cancer Institute of Canada Clinical Trials Group MY.11 trial D.J. White MD MSc,*
More informationPosttransplantation Maintenance Therapy and Optimal Frontline Therapy in Myeloma
CONTROVERSIES AND UPDATES IN MULTIPLE MYELOMA Posttransplantation Maintenance Therapy and Optimal Frontline Therapy in Myeloma Donna E. Reece 1 1 Princess Margaret Hospital, Toronto, ON One of the major
More informationHighlights in multiple myeloma
3 CONGRESS HIGHLIGHTS Highlights in multiple myeloma P. Vlummens, MD SUMMARY Multiple myeloma (MM) remains a devastating disease, even in the era of novel agents. As such, the search for new treatment
More informationA novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial
Europe PMC Funders Group Author Manuscript Published in final edited form as: Leukemia. 2012 February ; 26(2): 349 355. doi:10.1038/leu.2011.204. A novel prognostic model in myeloma based on co-segregating
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationJMSCR Vol 04 Issue 05 Page May 2016
www.jmscr.igmpublication.org Impact Factor 5.244 Index Copernicus Value: 5.88 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: http://dx.doi.org/10.18535/jmscr/v4i5.13 Interphase Fluorescence in Situ Hybridization
More informationExperience with bortezomib (Velcade) in multiple myeloma. Peter Černelč Clinical center Ljubljana Department of Haematology
Experience with bortezomib (Velcade) in multiple myeloma Peter Černelč Clinical center Ljubljana Department of Haematology Our experience with bortezomib (Velcade) in multiple myeloma 1. Our first experience
More informationIMiDs (Immunomodulatory drugs) and Multiple Myeloma
www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com
More informationJunru Liu*, Juan Li*, Beihui Huang, Dong Zheng, Mei Chen, Zhenhai Zhou, Duorong Xu, Waiyi Zou
Original Article Determining the optimal time for bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplant in the treatment of multiple myeloma Junru Liu*, Juan
More informationClinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient Upfront Transplant Versus Maintenance Therapy
Clinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient Upfront Transplant Versus Maintenance Therapy Noa Biran, MD, and David Vesole, MD, PhD Introduction High dose chemotherapy
More informationIl trattamento del Mieloma su stratificazione di rischio: è oggi possibile?
Il trattamento del Mieloma su stratificazione di rischio: è oggi possibile? Francesca Gay, MD Divisione Ematologia 1 AO Città della Salute e della Scienza, Torino, Italy Focus sul MM 2014 Cagliari, 30-31
More informationMAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA. Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health
MAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health Disclosures I have no significant conflicts of interest to disclose.
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationForms Revision: Myeloma Changes
Sharing knowledge. Sharing hope. Forms Revision: Myeloma Changes J. Brunner, PA-C and A. Dispenzieri, MD February 2013 Disclosures Janet Brunner, PA-C I have no relevant conflicts of interest to disclose.
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationwhich to base economic assessment of the products available to treat this hematologic
special feature Measuring Value of Multiple Myeloma Therapies by Gary M. Owens, MD, Gary Owens Associates As recent therapies for multiple myeloma (MM) have provided significant improvements in the prognosis
More informationClaPD (Clarithromycin/[Biaxin ], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma
ClaPD (Clarithromycin/[Biaxin ], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Tomer Mark 1, Angelique Boyer 1, Adriana Rossi 1, Manan Shah 1, Roger Pearse 1, Faiza Zafar
More informationBiology of Blood and Marrow Transplantation 12: (2006) 2006 American Society for Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation 12:837-844 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1208-0006$32.00/0 doi:10.1016/j.bbmt.2006.04.006 New Staging Systems
More informationHow I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
More informationDiagnosis and therapy of multiple myeloma
REVIEW Korean J Intern Med 2013;28:263-273 Diagnosis and therapy of multiple myeloma Antonio Palumbo and Chiara Cerrato Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Città
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationRisk stratification in the older patient; what are our priorities?
Risk stratification in the older patient; what are our priorities? Sonja Zweegman MD PhD Amsterdam The Netherlands Negative impact of age on survival Meta-analysis of European trials (MP vs MPT, VMP vs
More informationSafe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma
original articles Annals of Oncology Annals of Oncology 27: 902 907, 2016 doi:10.1093/annonc/mdw017 Published online 19 January 2016 Safe and prolonged survival with long-term exposure to pomalidomide
More informationTerapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More informationManaging Newly Diagnosed Multiple Myeloma
Managing Newly Diagnosed Multiple Myeloma 26 Jan 2018 Alfred Garfall, MD Assistant Professor of Medicine Diagnosis of Multiple Myeloma Traditional criteria: Monoclonal plasma cells + attributable CRAB
More informationKalyan Nadiminti, MBBS 4/13/18
A Single Autologous Stem Cell Transplant (ASCT) followed by two years of post-transplant therapy is safe in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Preliminary Results from the Prospective
More informationInduction Therapy in Transplant Eligible MM 2 December Tontanai Numbenjapon, M.D.
Induction Therapy in Transplant Eligible MM 2 December 2017 Tontanai Numbenjapon, M.D. What we need from induction therapy in NDMM Depth of response: MRD-negative, scr, CR Longest response Acceptable toxicity
More informationUK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook
UK Myeloma Research Alliance Myeloma XII study (ACCoRD): Augmented Conditioning & Consolidation in Relapsed Disease UK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook Sponsor ID: Pending
More informationRisk Stratification in Newly Diagnosed Transplant-Eligible Multiple Myeloma
Risk Stratification in Newly Diagnosed Transplant-Eligible Multiple Myeloma 2 Megan H. Jagosky, Alankrita Taneja, and Manisha Bhutani 2.1 Introduction Complex interplay between biology, chromosomal abnormalities,
More informationInternational Myeloma Foundation Patient and Family Seminar
International Myeloma Foundation Patient and Family Seminar Vienna, Austria May 6 th, 2006 New Development in Diagnosis & Treatments Brian G.M. Durie, M.D., Chairman International Myeloma Foundation What
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationOptimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice
REVIEW Korean J Intern Med 2016;31:809-819 Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice Ho Sup Lee 1 and Chang-Ki Min 2 1 Department of Internal Medicine,
More informationMaintenance therapy after autologous transplantation
Maintenance therapy after autologous transplantation Sonja Zweegman MD PhD Department of Hematology Amsterdam The Netherlands Disclosures Research funding from Celgene, Takeda and Janssen Participation
More informationTiming of Transplant for Multiple Myeloma
Timing of Transplant for Multiple Myeloma Wenming CHEN Beijing Chaoyang Hospital Capital Medical University Multiple myeloma resrarch center of Beijing Initial Approach to Treatment of Myeloma Nontransplantation
More informationMYELOMA MAINTENANCE BEST PRACTICES:
MYELOMA MAINTENANCE BEST PRACTICES: POST THERAPY & POST TRANSPLANT Aric Hall, MD Assistant Professor University of Wisconsin Hospital and Clinics INTRODUCTION MYELOMA Clonal plasma cell malignancy leading
More informationTreatment Strategies for Transplant-ineligible NDMM Patients
1 Treatment Strategies for Transplant-ineligible NDMM Patients Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Multiple Myeloma affects primarily
More informationIs Myeloma Curable in 2012?
Is Myeloma Curable in 2012? YES Cure is living long enough to die of another cause April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist,
More informationLiving Well with Myeloma Teleconference Series Thursday, March 24 th :00 PM Pacific/5:00 PM Mountain 6:00 PM Central/7:00 PM Eastern
Living Well with Myeloma Teleconference Series Thursday, March 24 th 216 4: PM Pacific/5: PM Mountain 6: PM Central/7: PM Eastern Speakers Dr. Brian Durie, IMF Chairman Cedars Sinai Samuel Oschin Cancer
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationMULTIPLE MYELOMA TREATMENT REGIMENS (Part 1 of 9)
MULTIPLE MYELOMA TREATMENT S (Part 1 of 9) Clinical Trials: The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration,
More informationLong-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis
Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis Morie A. Gertz, Martha Q. Lacy, John A. Lust, Philip R. Greipp, Thomas E. Witzig, and Robert A.
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationNovel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma
Novel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma Ravi Vij, MD MBA Professor of Medicine Washington University School of Medicine Section of Stem Cell Transplant
More informationMajor Diagnostic Criteria
Multiple Myeloma Elizabeth Ann Coleman, PhD, RNP, AOCN Professor and Chair, Dept. of Nursing Science Cooper Chair in Oncology Nursing, College of Nursing Professor, Dept. of Internal Medicine, College
More informationA Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Jatin J. Shah, MD 1, Edward A. Stadtmauer, MD 2, Rafat
More informationMULTIPLE MYELOMA TREATMENT REGIMENS (Part 1 of 9)
MULTIPLE MYELOMA TREATMENT S (Part 1 of 9) Clinical Trials: The National Comprehensive Candcer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer
More informationClinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis
OPEN Citation: Blood Cancer Journal (2014) 4, e239; doi:10.1038/bcj.2014.55 2014 Macmillan Publishers Limited All rights reserved 2044-5385/14 www.nature.com/bcj ORIGINAL ARTICLE Clinical features and
More informationCME Information: Multiple Myeloma: 2016 update on Diagnosis, Risk-stratification and Management
CME ARTICLE AJH CME Information: Multiple Myeloma: 2016 update on Diagnosis, Risk-stratification and Management CME Editor: Ayalew Tefferi, M.D. Author: S. Vincent Rajkumar, M.D. If you wish to receive
More informationPublished Ahead of Print on November 8, 2013, as doi: /haematol Copyright 2013 Ferrata Storti Foundation.
Published Ahead of Print on November 8, 2013, as doi:10.3324/haematol.2013.088211. Copyright 2013 Ferrata Storti Foundation. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with
More informationAutologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy
Autologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy Donna E. Reece, M.D. Princess Margaret Hospital Toronto, ON CANADA 10 December 2011 ASCT in Myeloma..
More informationCurrent Management of Multiple Myeloma. December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C.
Current Management of Multiple Myeloma December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C. Disclosures Honoraria Speaker Celgene, Janssen, Novartis Celgene, Janssen Research Support Celgene
More informationMedical Policy Title: HDC Progenitor Cell ARBenefits Approval: 02/08/2012
Medical Policy Title: HDC Progenitor Cell ARBenefits Approval: 02/08/2012 Support AL Amyloidosis (Light Chain Amyloidosis) Effective Date: 01/01/2013 Document: ARB0413:01 Revision Date: 10/24/2012 Code(s):
More information